Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal

作者：Reddy Sujan T^*; Cossey T C; Savitz Sean I; Grotta James C

来源：Current Neurology and Neuroscience Reports, 2017, 17(9): 67.

DOI：10.1007/s11910-017-0774-6

• NOAC
• Newer oral anticoagulants
• Reversal agents
• NVAF
• Stroke
• Antidote for NOAC

Purpose of Review An 80-year-old man presents with an acute right hemiparesis and National Institutes of Health Stroke Scale (NIHSS) of 25, 14 h after taking dabigatran. Activated partial thromboplastin time (aPTT) is 42.8 s. Arteriogram demonstrates left internal carotid artery thrombosis. What is the appropriate management of this patient with acute ischemic stroke while on a NOAC?
Recent Findings Idarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs.
Summary In this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.

• 出版日期2017-9